Structured evidence table for NAC Respiratory Infection Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| NAC Respiratory Infection Meta-Analysis | This document consolidates existing evidence to this effect, and adds insights from practicing clinicians to guide about use of NAC in clinical practice. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| NAC Respiratory Infection Meta-Analysis | Conclusion This consensus underscores the role of NAC in chronic respiratory diseases beyond its mucolytic properties and reiterates that NAC's antioxidant, anti-inflammatory, immunomodulatory and anti-biofilm properties provide significant clinical utility. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| NAC Respiratory Infection Meta-Analysis | While promising for TB and respiratory infections, further evidence is required. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| NAC Respiratory Infection Meta-Analysis | Background N-acetylcysteine (NAC) is a key precursor of glutathione (GSH), the lung's principal antioxidant. | 2 | Barne M (2026) | N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR). |
| NAC Respiratory Infection Meta-Analysis | Clinical evidence indicates that NAC and erdosteine can reduce exacerbation rates in COPD, carbocisteine shows benefit with prolonged administration, and dornase alfa remains a cornerstone in CF management. | 4 | Larobina D (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. |
| NAC Respiratory Infection Meta-Analysis | Emerging strategies, such as agents targeting mucin-DNA interactions and advanced inhalation delivery systems, promise improved specificity and durability. | 4 | Larobina D (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. |
| NAC Respiratory Infection Meta-Analysis | Muco-obstructive lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and bronchiectasis, are characterized by the accumulation of highly viscoelastic mucus that compromises mucociliary clearance and fosters infection and inflammation. | 4 | Larobina D (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. |
| NAC Respiratory Infection Meta-Analysis | Mucoactive therapy, encompassing both true mucolytics and non-cleaving agents, seeks to restore airway patency by altering mucus structure, hydration, and transport properties, yet its clinical impact remains variable. | 4 | Larobina D (2026) | Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. |
Source documents